ID   ANGL3_MOUSE             Reviewed;         455 AA.
AC   Q9R182;
DT   08-NOV-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   07-APR-2021, entry version 151.
DE   RecName: Full=Angiopoietin-related protein 3;
DE   AltName: Full=Angiopoietin-like protein 3;
DE   Contains:
DE     RecName: Full=ANGPTL3(17-224);
DE   Flags: Precursor;
GN   Name=Angptl3;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=10644446; DOI=10.1006/geno.1999.6041;
RA   Conklin D., Gilbertson D., Taft D.W., Maurer M.F., Whitmore T.E.,
RA   Smith D.L., Walker K.M., Chen L.H., Wattler S., Nehls M., Lewis K.B.;
RT   "Identification of a mammalian angiopoietin-related protein expressed
RT   specifically in liver.";
RL   Genomics 62:477-482(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION.
RX   PubMed=11877390; DOI=10.1074/jbc.m109768200;
RA   Camenisch G., Pisabarro M.T., Sherman D., Kowalski J., Nagel M., Hass P.,
RA   Xie M.H., Gurney A., Bodary S., Liang X.H., Clark K., Beresini M.,
RA   Ferrara N., Gerber H.P.;
RT   "ANGPTL3 stimulates endothelial cell adhesion and migration via integrin
RT   alpha vbeta 3 and induces blood vessel formation in vivo.";
RL   J. Biol. Chem. 277:17281-17290(2002).
RN   [4]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=11788823; DOI=10.1038/ng814;
RA   Koishi R., Ando Y., Ono M., Shimamura M., Yasumo H., Fujiwara T.,
RA   Horikoshi H., Furukawa H.;
RT   "Angptl3 regulates lipid metabolism in mice.";
RL   Nat. Genet. 30:151-157(2002).
RN   [5]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=12909640; DOI=10.1074/jbc.m302861200;
RA   Ono M., Shimizugawa T., Shimamura M., Yoshida K., Noji-Sakikawa C.,
RA   Ando Y., Koishi R., Furukawa H.;
RT   "Protein region important for regulation of lipid metabolism in
RT   angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo.";
RL   J. Biol. Chem. 278:41804-41809(2003).
RN   [6]
RP   FUNCTION.
RX   PubMed=12671033; DOI=10.1194/jlr.m300031-jlr200;
RA   Ando Y., Shimizugawa T., Takeshita S., Ono M., Shimamura M., Koishi R.,
RA   Furukawa H.;
RT   "A decreased expression of angiopoietin-like 3 is protective against
RT   atherosclerosis in apoE-deficient mice.";
RL   J. Lipid Res. 44:1216-1223(2003).
RN   [7]
RP   INDUCTION.
RX   PubMed=15336575; DOI=10.1016/j.bbrc.2004.08.024;
RA   Shimamura M., Matsuda M., Ando Y., Koishi R., Yasumo H., Furukawa H.,
RA   Shimomura I.;
RT   "Leptin and insulin down-regulate angiopoietin-like protein 3, a plasma
RT   triglyceride-increasing factor.";
RL   Biochem. Biophys. Res. Commun. 322:1080-1085(2004).
RN   [8]
RP   INDUCTION.
RX   PubMed=15863837; DOI=10.1194/jlr.m500005-jlr200;
RA   Ge H., Cha J.Y., Gopal H., Harp C., Yu X., Repa J.J., Li C.;
RT   "Differential regulation and properties of angiopoietin-like proteins 3 and
RT   4.";
RL   J. Lipid Res. 46:1484-1490(2005).
RN   [9]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=16081640; DOI=10.1210/en.2005-0476;
RA   Koester A., Chao Y.B., Mosior M., Ford A., Gonzalez-DeWhitt P.A.,
RA   Hale J.E., Li D., Qiu Y., Fraser C.C., Yang D.D., Heuer J.G.,
RA   Jaskunas S.R., Eacho P.;
RT   "Transgenic angiopoietin-like (angptl)4 overexpression and targeted
RT   disruption of angptl4 and angptl3: regulation of triglyceride metabolism.";
RL   Endocrinology 146:4943-4950(2005).
RN   [10]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=16508209; DOI=10.1538/expanim.55.27;
RA   Fujimoto K., Koishi R., Shimizugawa T., Ando Y.;
RT   "Angptl3-null mice show low plasma lipid concentrations by enhanced
RT   lipoprotein lipase activity.";
RL   Exp. Anim. 55:27-34(2006).
RN   [11]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=17110602; DOI=10.1161/01.atv.0000252827.51626.89;
RA   Shimamura M., Matsuda M., Yasumo H., Okazaki M., Fujimoto K., Kono K.,
RA   Shimizugawa T., Ando Y., Koishi R., Kohama T., Sakai N., Kotani K.,
RA   Komuro R., Ishida T., Hirata K., Yamashita S., Furukawa H., Shimomura I.;
RT   "Angiopoietin-like protein3 regulates plasma HDL cholesterol through
RT   suppression of endothelial lipase.";
RL   Arterioscler. Thromb. Vasc. Biol. 27:366-372(2007).
RN   [12]
RP   FUNCTION, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=17681148; DOI=10.1016/j.cmet.2007.07.009;
RA   Jin W., Wang X., Millar J.S., Quertermous T., Rothblat G.H., Glick J.M.,
RA   Rader D.J.;
RT   "Hepatic proprotein convertases modulate HDL metabolism.";
RL   Cell Metab. 6:129-136(2007).
RN   [13]
RP   FUNCTION.
RX   PubMed=20633534; DOI=10.1016/j.bbrc.2010.07.027;
RA   Gao X., Xu H., Liu H., Rao J., Li Y., Zha X.;
RT   "Angiopoietin-like protein 3 regulates the motility and permeability of
RT   podocytes by altering nephrin expression in vitro.";
RL   Biochem. Biophys. Res. Commun. 399:31-36(2010).
RN   [14]
RP   FUNCTION, AND MUTAGENESIS OF ARG-221.
RX   PubMed=20581395; DOI=10.1074/jbc.m110.144279;
RA   Liu J., Afroza H., Rader D.J., Jin W.;
RT   "Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through
RT   enhancing its cleavage by proprotein convertases.";
RL   J. Biol. Chem. 285:27561-27570(2010).
RN   [15]
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=20424482; DOI=10.1159/000313829;
RA   Jia R., Hong X., Li S., Haichun Y., Chuanming H.;
RT   "Expression of angiopoietin-like 3 associated with puromycin-induced
RT   podocyte damage.";
RL   Nephron Exp. Nephrol. 115:E38-E45(2010).
RN   [16]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=20959605; DOI=10.1182/blood-2010-06-291716;
RA   Zheng J., Huynh H., Umikawa M., Silvany R., Zhang C.C.;
RT   "Angiopoietin-like protein 3 supports the activity of hematopoietic stem
RT   cells in the bone marrow niche.";
RL   Blood 117:470-479(2011).
RN   [17]
RP   FUNCTION.
RX   PubMed=24294595; DOI=10.1155/2013/135608;
RA   Lin Y., Rao J., Zha X.L., Xu H.;
RT   "Angiopoietin-like 3 induces podocyte F-actin rearrangement through
RT   integrin alpha(V)beta(3)/FAK/PI3K pathway-mediated Rac1 activation.";
RL   Biomed. Res. Int. 2013:135608-135608(2013).
RN   [18]
RP   PROTEOLYTIC CLEAVAGE, MUTAGENESIS OF ARG-221 AND ARG-224, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=23918928; DOI=10.1074/jbc.m113.501304;
RA   Essalmani R., Susan-Resiga D., Chamberland A., Asselin M.C., Canuel M.,
RA   Constam D., Creemers J.W., Day R., Gauthier D., Prat A., Seidah N.G.;
RT   "Furin is the primary in vivo convertase of angiopoietin-like 3 and
RT   endothelial lipase in hepatocytes.";
RL   J. Biol. Chem. 288:26410-26418(2013).
RN   [19]
RP   FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=25338813; DOI=10.2337/db14-0647;
RA   Kim H.K., Shin M.S., Youn B.S., Kang G.M., Gil S.Y., Lee C.H., Choi J.H.,
RA   Lim H.S., Yoo H.J., Kim M.S.;
RT   "Regulation of energy balance by the hypothalamic lipoprotein lipase
RT   regulator Angptl3.";
RL   Diabetes 64:1142-1153(2015).
RN   [20]
RP   FUNCTION.
RX   PubMed=25954050; DOI=10.1194/jlr.m054882;
RA   Wang Y., Gusarova V., Banfi S., Gromada J., Cohen J.C., Hobbs H.H.;
RT   "Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion.";
RL   J. Lipid Res. 56:1296-1307(2015).
RN   [21]
RP   FUNCTION, INTERACTION WITH ITGB3, TISSUE SPECIFICITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=25710887; DOI=10.1038/pr.2015.38;
RA   Liu J., Gao X., Zhai Y., Shen Q., Sun L., Feng C., Rao J., Liu H., Zha X.,
RA   Guo M., Ma D., Zhang Z., Li R., Xu H.;
RT   "A novel role of angiopoietin-like-3 associated with podocyte injury.";
RL   Pediatr. Res. 77:732-739(2015).
RN   [22]
RP   FUNCTION.
RX   PubMed=26305978; DOI=10.1073/pnas.1515374112;
RA   Wang Y., McNutt M.C., Banfi S., Levin M.G., Holland W.L., Gusarova V.,
RA   Gromada J., Cohen J.C., Hobbs H.H.;
RT   "Hepatic ANGPTL3 regulates adipose tissue energy homeostasis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:11630-11635(2015).
CC   -!- FUNCTION: Acts in part as a hepatokine that is involved in regulation
CC       of lipid and glucose metabolism (PubMed:11788823, PubMed:12671033).
CC       Proposed to play a role in the trafficking of energy substrates to
CC       either storage or oxidative tissues in response to food intake
CC       (PubMed:26305978). Has a stimulatory effect on plasma triglycerides
CC       (TG), which is achieved by suppressing plasma TG clearance via
CC       inhibition of LPL activity; the function seems to be specific for the
CC       feeding conditions. The inhibition of LPL activity appears to be an
CC       indirect mechanism involving recruitment of proprotein convertases
CC       PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from
CC       the cell surface; the function does not require ANGPTL3 proteolytic
CC       cleavage but seems to be mediated by the N-terminal domain, and is not
CC       inhibited by GPIHBP1 (PubMed:12909640, PubMed:16081640,
CC       PubMed:20581395). Can inhibit endothelial lipase, causing increased
CC       plasma levels of high density lipoprotein (HDL) cholesterol and
CC       phospholipids; the cleaved N-terminal domain is more efficient than the
CC       uncleaved proprotein (PubMed:17681148). Can bind to adipocytes to
CC       activate lipolysis, releasing free fatty acids and glycerol (By
CC       similarity). Suppresses LPL specifically in oxidative tissues which is
CC       required to route very low density lipoprotein (VLDL)-TG to white
CC       adipose tissue (WAT) for storage in response to food; the function may
CC       involve cooperation with circulating, liver-derived ANGPTL8 and ANGPTL4
CC       expression in WAT (PubMed:26305978). Contributes to lower plasma levels
CC       of low density lipoprotein (LDL)-cholesterol by a mechanism that is
CC       independent of the canonical pathway implicating APOE and LDLR
CC       (PubMed:25954050). May stimulate hypothalamic LPL activity
CC       (PubMed:25338813). {ECO:0000250|UniProtKB:Q9Y5C1,
CC       ECO:0000269|PubMed:11788823, ECO:0000269|PubMed:12671033,
CC       ECO:0000269|PubMed:16081640, ECO:0000269|PubMed:17681148,
CC       ECO:0000269|PubMed:20581395, ECO:0000269|PubMed:25338813,
CC       ECO:0000269|PubMed:25954050, ECO:0000269|PubMed:26305978}.
CC   -!- FUNCTION: Involved in angiogenesis (PubMed:11877390). Binds to
CC       endothelial cells via integrin alpha-V/beta-3 (ITGAV:ITGB3), activates
CC       FAK, MAPK and Akt signaling pathways and induces cell adhesion and cell
CC       migration (By similarity). May increase the motility of podocytes.
CC       Secreted from podocytes, may modulate properties of glomerular
CC       endothelial cells involving integrin alpha-V/beta-3 and Akt signaling
CC       (By similarity). May induce actin filament rearrangements in podocytes
CC       implicating integrin alpha-V/beta-3 and Rac1 activation
CC       (PubMed:20633534, PubMed:24294595, PubMed:25710887). Binds to
CC       hematopoietic stem cells (HSC) and is involved in the regulation of HSC
CC       activity probably implicating down-regulation of IKZF1/IKAROS
CC       (PubMed:20959605). {ECO:0000250|UniProtKB:Q9Y5C1,
CC       ECO:0000269|PubMed:11877390, ECO:0000269|PubMed:20633534,
CC       ECO:0000269|PubMed:20959605, ECO:0000269|PubMed:24294595,
CC       ECO:0000269|PubMed:25710887}.
CC   -!- SUBUNIT: Interacts with ANGPTL8 (By similarity). Interacts with ITGB3.
CC       {ECO:0000250|UniProtKB:Q9Y5C1, ECO:0000269|PubMed:25710887}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:23918928}. Cell
CC       projection, lamellipodium {ECO:0000269|PubMed:25710887}.
CC       Note=Colocalized with HSPG2 and activated ITGB3 on podocytes.
CC       {ECO:0000269|PubMed:20424482, ECO:0000269|PubMed:25710887}.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in liver, weakly expressed
CC       in kidney and lung. Expressed in podocytes (at protein level).
CC       Expressed in hypothalamic neurons (at protein level). Expressed in bone
CC       marrow sinusoidal endothelial cells (at protein level).
CC       {ECO:0000269|PubMed:10644446, ECO:0000269|PubMed:20959605,
CC       ECO:0000269|PubMed:25338813, ECO:0000269|PubMed:25710887}.
CC   -!- INDUCTION: Down-regulated by insulin and leptin. Not regulated by
CC       nutritional status (fed/fasting) Up-regulated in podocytes by
CC       puromycin. Up-regulated after feeding in the hypothalamus.
CC       {ECO:0000269|PubMed:15336575, ECO:0000269|PubMed:15863837,
CC       ECO:0000269|PubMed:20424482, ECO:0000269|PubMed:25338813}.
CC   -!- DOMAIN: The fibrinogen C-terminal domain is sufficient to mediate
CC       endothelial cell adhesion. {ECO:0000250|UniProtKB:Q9Y5C1}.
CC   -!- PTM: In part proteolytically cleaved by proprotein convertases;
CC       proposed to be involved in activation. In primary hepatocytes is
CC       intracellularily predominantly processed by FURIN and extracellularily
CC       by FURIN and PCSK6/PACE4. In E18.5 embryos 75% of protein is found to
CC       be processed compared to 25 % in adults. {ECO:0000269|PubMed:17681148,
CC       ECO:0000269|PubMed:23918928}.
CC   -!- DISRUPTION PHENOTYPE: Low plasma levels of triglyceride, HDL
CC       cholesterol and HDL phospholipids, and non-esterified fatty acids
CC       (NEFA). Animals fed on high-fat, high-calorie (HFC) diet show reduced
CC       epididymal adipose tissue weight with no difference in adipocyte size.
CC       Hypotriglyceridemia with elevated postheparin plasma LPL activity is
CC       specifically observed in the fed state. Mice deficient in both Angptl3
CC       and Angptl4 show an additive effect on plasma triglycerides and did not
CC       survive past 2 months of age. {ECO:0000269|PubMed:11788823,
CC       ECO:0000269|PubMed:15336575, ECO:0000269|PubMed:16081640,
CC       ECO:0000269|PubMed:17110602}.
CC   -!- MISCELLANEOUS: Was suggested to inhibit LPL through a direct mechanism;
CC       however, the necessary concentrations to achieve the in vitro
CC       inhibition are at least 30-fold higher than ANGPTL3 plasma
CC       concentrations. {ECO:0000305|PubMed:20581395}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF162224; AAD45920.1; -; mRNA.
DR   EMBL; BC019491; AAH19491.1; -; mRNA.
DR   CCDS; CCDS38817.1; -.
DR   RefSeq; NP_038941.1; NM_013913.4.
DR   SMR; Q9R182; -.
DR   STRING; 10090.ENSMUSP00000030280; -.
DR   GlyGen; Q9R182; 5 sites.
DR   iPTMnet; Q9R182; -.
DR   PhosphoSitePlus; Q9R182; -.
DR   CPTAC; non-CPTAC-4016; -.
DR   MaxQB; Q9R182; -.
DR   PaxDb; Q9R182; -.
DR   PRIDE; Q9R182; -.
DR   ProteomicsDB; 296291; -.
DR   ABCD; Q9R182; 1 sequenced antibody.
DR   Antibodypedia; 19489; 492 antibodies.
DR   Ensembl; ENSMUST00000030280; ENSMUSP00000030280; ENSMUSG00000028553.
DR   GeneID; 30924; -.
DR   KEGG; mmu:30924; -.
DR   UCSC; uc008tur.1; mouse.
DR   CTD; 27329; -.
DR   MGI; MGI:1353627; Angptl3.
DR   eggNOG; KOG2579; Eukaryota.
DR   GeneTree; ENSGT00940000156746; -.
DR   HOGENOM; CLU_038628_2_0_1; -.
DR   InParanoid; Q9R182; -.
DR   OMA; GHFNCPE; -.
DR   OrthoDB; 357340at2759; -.
DR   PhylomeDB; Q9R182; -.
DR   TreeFam; TF329953; -.
DR   Reactome; R-MMU-8963889; Assembly of active LPL and LIPC lipase complexes.
DR   BioGRID-ORCS; 30924; 2 hits in 52 CRISPR screens.
DR   PRO; PR:Q9R182; -.
DR   Proteomes; UP000000589; Chromosome 4.
DR   RNAct; Q9R182; protein.
DR   Bgee; ENSMUSG00000028553; Expressed in liver and 92 other tissues.
DR   ExpressionAtlas; Q9R182; baseline and differential.
DR   Genevisible; Q9R182; MM.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; IBA:GO_Central.
DR   GO; GO:0005769; C:early endosome; IDA:MGI.
DR   GO; GO:0005576; C:extracellular region; ISS:MGI.
DR   GO; GO:0005615; C:extracellular space; ISO:MGI.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:MGI.
DR   GO; GO:0030027; C:lamellipodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0004857; F:enzyme inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0008083; F:growth factor activity; ISO:MGI.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0005178; F:integrin binding; ISS:UniProtKB.
DR   GO; GO:0004859; F:phospholipase inhibitor activity; ISO:MGI.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0055090; P:acylglycerol homeostasis; IMP:BHF-UCL.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0048844; P:artery morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0007160; P:cell-matrix adhesion; ISS:UniProtKB.
DR   GO; GO:0042632; P:cholesterol homeostasis; IMP:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; ISO:MGI.
DR   GO; GO:0006631; P:fatty acid metabolic process; ISO:MGI.
DR   GO; GO:0006071; P:glycerol metabolic process; ISO:MGI.
DR   GO; GO:0055088; P:lipid homeostasis; ISO:MGI.
DR   GO; GO:0019915; P:lipid storage; ISO:MGI.
DR   GO; GO:0051005; P:negative regulation of lipoprotein lipase activity; ISO:MGI.
DR   GO; GO:0010519; P:negative regulation of phospholipase activity; IMP:BHF-UCL.
DR   GO; GO:0009395; P:phospholipid catabolic process; ISO:MGI.
DR   GO; GO:0055091; P:phospholipid homeostasis; IMP:BHF-UCL.
DR   GO; GO:0006644; P:phospholipid metabolic process; ISO:MGI.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0050996; P:positive regulation of lipid catabolic process; ISO:MGI.
DR   GO; GO:0045834; P:positive regulation of lipid metabolic process; NAS:UniProtKB.
DR   GO; GO:0009725; P:response to hormone; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; ISO:MGI.
DR   GO; GO:0070328; P:triglyceride homeostasis; IMP:BHF-UCL.
DR   GO; GO:0006641; P:triglyceride metabolic process; NAS:UniProtKB.
DR   CDD; cd00087; FReD; 1.
DR   InterPro; IPR036056; Fibrinogen-like_C.
DR   InterPro; IPR002181; Fibrinogen_a/b/g_C_dom.
DR   Pfam; PF00147; Fibrinogen_C; 1.
DR   SMART; SM00186; FBG; 1.
DR   SUPFAM; SSF56496; SSF56496; 1.
DR   PROSITE; PS51406; FIBRINOGEN_C_2; 1.
PE   1: Evidence at protein level;
KW   Angiogenesis; Cell adhesion; Cell projection; Coiled coil; Disulfide bond;
KW   Glycoprotein; Heparin-binding; Lipid metabolism; Reference proteome;
KW   Secreted; Signal.
FT   SIGNAL          1..16
FT                   /evidence="ECO:0000255"
FT   CHAIN           17..455
FT                   /note="Angiopoietin-related protein 3"
FT                   /id="PRO_0000009123"
FT   CHAIN           17..224
FT                   /note="ANGPTL3(17-224)"
FT                   /evidence="ECO:0000305|PubMed:12909640,
FT                   ECO:0000305|PubMed:23918928"
FT                   /id="PRO_0000435905"
FT   DOMAIN          237..455
FT                   /note="Fibrinogen C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00739"
FT   REGION          17..207
FT                   /note="Sufficient to inhibit LIPG/EL phospholipase
FT                   activity"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y5C1"
FT   REGION          17..165
FT                   /note="Sufficient to inhibit LPL lipase activity"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y5C1,
FT                   ECO:0000269|PubMed:20581395"
FT   REGION          32..56
FT                   /note="Required for inhibition of LPL lipase activity"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y5C1"
FT   COILED          85..206
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        115
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        226
FT                   /note="O-linked (GlcNAc) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y5C1"
FT   CARBOHYD        232
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        296
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        357
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        246..274
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00739"
FT   DISULFID        394..408
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00739"
FT   MUTAGEN         221
FT                   /note="R->A: Abolishes proteolytical cleavage."
FT                   /evidence="ECO:0000269|PubMed:20581395,
FT                   ECO:0000269|PubMed:23918928"
FT   MUTAGEN         224
FT                   /note="R->A: Abolishes proteolytical cleavage."
FT                   /evidence="ECO:0000269|PubMed:23918928"
SQ   SEQUENCE   455 AA;  52543 MW;  31609D3700D3F33D CRC64;
     MHTIKLFLFV VPLVIASRVD PDLSSFDSAP SEPKSRFAML DDVKILANGL LQLGHGLKDF
     VHKTKGQIND IFQKLNIFDQ SFYDLSLRTN EIKEEEKELR RTTSTLQVKN EEVKNMSVEL
     NSKLESLLEE KTALQHKVRA LEEQLTNLIL SPAGAQEHPE VTSLKSFVEQ QDNSIRELLQ
     SVEEQYKQLS QQHMQIKEIE KQLRKTGIQE PSENSLSSKS RAPRTTPPLQ LNETENTEQD
     DLPADCSAVY NRGEHTSGVY TIKPRNSQGF NVYCDTQSGS PWTLIQHRKD GSQDFNETWE
     NYEKGFGRLD GEFWLGLEKI YAIVQQSNYI LRLELQDWKD SKHYVEYSFH LGSHETNYTL
     HVAEIAGNIP GALPEHTDLM FSTWNHRAKG QLYCPESYSG GWWWNDICGE NNLNGKYNKP
     RTKSRPERRR GIYWRPQSRK LYAIKSSKMM LQPTT
//
